Central geographic atrophy vs. neovascular age–related macular degeneration: differences in longitudinal vision-related quality of life

• Published in: Graefe's archive for clinical and experimental ophthalmology 2021-02, Vol.259 (2), p.307-316
• Main Authors: Ahluwalia, Aneesha, Shen, Liangbo L., Del Priore, Lucian V.
• Format: Article
• Language: English
• Subjects: Age; Angiogenesis Inhibitors; Atrophy; Cross-Sectional Studies; Eye diseases; Female; Geographic Atrophy - diagnosis; Geographic Atrophy - epidemiology; Humans; Macular degeneration; Male; Medicine; Medicine & Public Health; Ophthalmology; Phenotypes; Quality of Life; Retinal Disorders; Sickness Impact Profile; Surveys and Questionnaires; Vascular Endothelial Growth Factor A; Vision; Visual Acuity; Visual perception; Wet Macular Degeneration - diagnosis
• ISSN: 0721-832X; 1435-702X
• DOI: 10.1007/s00417-020-04892-5

Objective Prior studies of vision-related quality of life (VRQoL) have examined advanced age-related macular degeneration (AMD) as a single group or focused on neovascular AMD (nAMD), even though advanced AMD can refer to either central geographic atrophy (GA) or nAMD. We compared the natural progression of VRQoL in central GA versus nAMD. Methods We included Age-Related Eye Disease Study (AREDS) participants with central GA ( n = 206) or nAMD ( n = 198) who completed the National Eye Institute Visual Function Questionnaire (NEI-VFQ) between 1997 and 2005. The rate of change of VRQoL was calculated as the slopes of linear models fit to longitudinal individual-level NEI-VFQ scores. Multivariable regressions identified factors associated with experiencing a decline in VRQoL during the study period and cross-sectional VRQoL score. Results There was a minor decline in VRQoL prior to the development of nAMD but a significantly steeper decline after progression to nAMD (0.49 ± 2.91 vs. 3.30 ± 5.58 NEI-VFQ units/year; p < 0.001). The rates of VRQoL decline were similar before and after the development of central GA (1.99 ± 4.97 vs. 1.68 ± 4.65 NEI-VFQ units/year; p = 0.66). Prior to the development of advanced AMD, the rate of VRQoL decline was greater for participants destined to develop central GA versus nAMD ( p = 0.007), while postprogression to advanced disease, the rate was greater in nAMD compared with central GA ( p = 0.012). Female gender (odds ratio [OR] 2.61, 95% confidence interval [CI] 1.38-5.06; p = 0.003) and higher baseline VRQoL score (OR 1.03, 95% CI 1.01–1.06; p = 0.006) were independently associated with experiencing a longitudinal decline in VRQoL. Conclusion The natural progression of VRQoL differed in central GA versus nAMD, both before and after the development of advanced disease, suggesting that future studies should consider separating these phenotypes. Females and those with a higher baseline VRQoL were more likely to experience a longitudinal decline in VRQoL following progression to advanced AMD.